DOCSLIB.ORG

Supplementary Information Table 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Information Table 1 Supplementary Information Table 1 Probe M B Description NM_004253 1.12 10.49 PHOSPHOLIPASE A2-ACTIVATING PROTEIN (PLAA) NM_005084 1.40 8.01 PHOSPHOLIPASE A2, GROUP VII (PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, PLASMA) (PLA2G7) NM_005017 0.89 7.71 PHOSPHATE CYTIDYLYLTRANSFERASE 1, CHOLINE, ALPHA ISOFORM (PCYT1A) NM_020244 1.41 7.09 CHOLINEPHOSPHOTRANSFERASE 1 (CHPT1) NM_001277 0.79 5.78 CHOLINE KINASE (CHK) NM_002660 0.80 3.49 PHOSPHOLIPASE C, GAMMA 1 (FORMERLY SUBTYPE 148) (PLCG1) NM_005090 -0.70 3.34 PHOSPHOLIPASE A2, GROUP IVB (CYTOSOLIC) (PLA2G4B) AJ272267 0.78 1.15 HOMO SAPIENS PARTIAL FOR CHOLINE DEHYDROGENASE (CHDH GENE) NM_003706 0.33 0.19 PHOSPHOLIPASE A2, GROUP IVC (CYTOSOLIC, CALCIUM-INDEPENDENT) (PLA2G4C) 949518CB1 -0.30 -0.49 PHOSPHOLIPASE A2, GROUP IB (PANCREAS) (PLA2G1B), NUCLEAR GENE ENCODING MITOCHONDRIAL PROTEIN NM_003574 -0.44 -0.82 VAMP (VESICLE-ASSOCIATED MEMBRANE PROTEIN)-ASSOCIATED PROTEIN A (33KD) (VAPA) NM_006330 0.76 -2.28 LYSOPHOSPHOLIPASE I (LYPLA1) NM_002662 0.66 -2.68 PHOSPHOLIPASE D1, PHOPHATIDYLCHOLINE-SPECIFIC (PLD1) NM_004573 -0.28 -2.95 PHOSPHOLIPASE C, BETA 2 (PLCB2) NM_003560 0.31 -3.40 PHOSPHOLIPASE A2, GROUP VI (CYTOSOLIC, CALCIUM-INDEPENDENT) (PLA2G6) NM_002661 0.22 -4.40 PHOSPHOLIPASE C, GAMMA 2 (PHOSPHATIDYLINOSITOL-SPECIFIC) (PLCG2) NM_000300 0.60 -4.43 PHOSPHOLIPASE A2, GROUP IIA (PLATELETS, SYNOVIAL FLUID) (PLA2G2A), NUCLEAR GENE ENCODING MITOCHONDRIAL PROTEIN NM_002663 0.30 -4.45 PHOSPHOLIPASE D2 (PLD2) NM_000933 0.37 -4.45 PHOSPHOLIPASE C, BETA 4 (PLCB4) 159053.3 -0.20 -5.76 PHOSPHOLIPASE A2, GROUP IB (PANCREAS) (PLA2G1B), NUCLEAR GENE ENCODING MITOCHONDRIAL PROTEIN 2899129CB1 -0.15 -6.32 LYSOPHOSPHOLIPASE 3 (LYSOSOMAL PHOSPHOLIPASE A2) (LYPLA3) NM_006226 0.28 -6.37 PHOSPHOLIPASE C, EPSILON (PLCE) NM_000929 -0.33 -6.72 PHOSPHOLIPASE A2, GROUP V (PLA2G5) NM_015715 -0.14 -6.78 GROUP III SECRETED PHOSPHOLIPASE A2 (GIII-SPLA2) 232063 -0.09 -6.88 CDNA FLJ36326 FIS, CLONE THYMU2005576, MODERATELY SIMILAR TO MUS MUSCULUS GROUP IIF SECRETED PHOSPHOLIPASE A2 (PLA2G2F) AF038440 0.47 -6.92 PHOSPHOLIPASE D2 (PLD2) , SPLICE VARIANT HPLD2A, COMPLETE CDS AF263613 -0.48 -7.16 MEMBRANE-ASSOCIATED CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 GAMMA , COMPLETE CDS NM_021213 0.06 -7.36 PHOSPHATIDYLCHOLINE TRANSFER PROTEIN (PCTP) NM_007366 0.07 -7.38 PHOSPHOLIPASE A2 RECEPTOR 1, 180KD (PLA2R1) NM_032562 -0.10 -7.39 PHOSPHOLIPASE A2, GROUP XIII (PLA2G13) NM_003561 0.08 -7.40 PHOSPHOLIPASE A2, GROUP X (PLA2G10) NM_012400 -0.07 -7.46 PHOSPHOLIPASE A2, GROUP IID (PLA2G2D) AB005216 -0.09 -7.53 FOR NCK, ASH AND PHOSPHOLIPASE C GAMMA-BINDING PROTEIN NAP4, PARTIAL CDS NM_000932 -0.07 -7.55 PHOSPHOLIPASE C, BETA 3 (PHOSPHATIDYLINOSITOL-SPECIFIC) (PLCB3) NM_007260 -0.03 -7.66 LYSOPHOSPHOLIPASE II (LYPLA2) NM_006090 -0.05 -7.69 CHOLINE/ETHANOLAMINEPHOSPHOTRANSFERASE (CEPT1) NM_004845 0.04 -7.71 PHOSPHATE CYTIDYLYLTRANSFERASE 1, CHOLINE, BETA ISOFORM (PCYT1B) NM_020549 -0.02 -7.74 CHOLINE ACETYLTRANSFERASE (CHAT), TRANSCRIPT VARIANT M 1503336.16 0.03 -7.75 PHOSPHOLIPASE A2, GROUP IB (PANCREAS) (PLA2G1B), NUCLEAR GENE ENCODING MITOCHONDRIAL PROTEIN NM_005198 -0.01 -7.75 CHOLINE KINASE-LIKE (CHKL) NM_006225 0.00 -7.75 PHOSPHOLIPASE C, DELTA 1 (PLCD1) Table 1 Differential expression of genes involved in choline metabolism between HCT116 wild-type and p300- cells. The values, M and B, were calculated for each element on the array. M is a measure of differential gene expression - and is based on log2 of the ratio p300 /HCT116. B is a statistic for likelihood of difference used to rank genes. Highlighted genes represent genes involved in choline metabolism where expression levels appear to be significantly different between p300- and HCT116 wild-type cells. .
Load more
Loading...
Loading...

—— Preview end. ——

Recommended publications
  • Novel Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Provide New Insights Into M1-Dependent Synaptic Plasticity and Receptor Signaling
    Novel allosteric modulators of the M1 muscarinic acetylcholine receptor provide new insights into M1-dependent synaptic plasticity and receptor signaling By Sean P Moran Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Neuroscience December 14, 2019 Nashville, Tennessee Approved: Sachin Patel M.D., Ph.D. Colleen Niswender, Ph.D. Danny Winder, Ph.D. P. Jeffrey Conn, Ph.D. ACKNOWLEDGMENTS Throughout my scientific career, there have been many people instrumental in my scientific journey. I would first like to thank Jeff Conn for providing a very supportive research atmosphere, for always making me laugh, for his insight and constructive criticism in our one-on-one meetings and for occasionally getting my name correct. I would also like to thank my thesis committee of Sachin Patel, Colleen Niswender and Danny Winder for their unwavering support during my time here at Vanderbilt. Additionally, I have very much enjoyed collaborating with Jerri Rook on many projects and would like to thank her for her sage behavioral pharmacology advice over the years. Also, thanks to the many members of the VCNDD including: Zixiu, Craig, Jon Dickerson, Dan Foster, Max, Nicole, Mark and Carrie who provided intellectual contributions, technical training or research support throughout my graduate career. Thank you to the many other members of the VCNDD, past and present, that have contributed to my various projects over the years. Thanks to the better half of Shames (James). I will our miss our long winded, highly pedantic and semantic discussions that occasionally touched on pharmacology topics…and thanks for making me not homeless.
    [Show full text]
  • Genetic Studies of Bipolar Disorder in Patients Selectedby Their Treatment
    medigraphic Artemisaen línea Salud Mental 2008;31:431-440 Genetic studies of bipolar disorder Genetic studies of bipolar disorder in patients selected by their treatment response* Abigail Ortiz-Domínguez,1 Martin Alda1 Conferencia magistral SUMMARY rapid cycling and non-episodic course in the lamotrigine group) and co-morbidity, with the lamotrigine-responder group showing a higher Bipolar disorder (BD) is a major mood disorder with several genes frequency of panic attacks and substance abuse. of moderate or small effect contributing to the genetic susceptibility. In conclusion, pharmacogenetic studies may provide important It is also likely heterogeneous, which stimulated efforts to refine its clues to the nature of bipolar disorder and the response to long term clinical phenotype, studies investigating the link between BD treatment. susceptibility and response to a specific mood stabilizer appear to be one of the promising directions. Key words: Lithium response, pharmacogenetic, probands. In particular, excellent response to lithium prophylaxis has been described as a clinical marker of a more homogeneous subgroup of BD, characterized by an episodic course, low rates of co-morbid RESUMEN conditions, absence of rapid cycling, and a strong genetic loading. These results also suggest that lithium response clusters in families El trastorno bipolar (TB) es un trastorno afectivo con varios genes, de (independent of the increased familial loading for affective disorders), efecto leve o moderado, que contribuyen a su susceptibilidad. Es likely on a genetic basis. asimismo un trastorno heterogéneo, lo que ha estimulado diversas For almost 40 years, clinical studies have pointed to differences iniciativas para refinar el fenotipo de los pacientes con este trastor- between lithium responders (LR) and non-responders (LNR).
    [Show full text]
  • Role of Phospholipases in Adrenal Steroidogenesis
    229 1 W B BOLLAG Phospholipases in adrenal 229:1 R29–R41 Review steroidogenesis Role of phospholipases in adrenal steroidogenesis Wendy B Bollag Correspondence should be addressed Charlie Norwood VA Medical Center, One Freedom Way, Augusta, GA, USA to W B Bollag Department of Physiology, Medical College of Georgia, Augusta University (formerly Georgia Regents Email University), Augusta, GA, USA wbollag@augusta.edu Abstract Phospholipases are lipid-metabolizing enzymes that hydrolyze phospholipids. In some Key Words cases, their activity results in remodeling of lipids and/or allows the synthesis of other f adrenal cortex lipids. In other cases, however, and of interest to the topic of adrenal steroidogenesis, f angiotensin phospholipases produce second messengers that modify the function of a cell. In this f intracellular signaling review, the enzymatic reactions, products, and effectors of three phospholipases, f phospholipids phospholipase C, phospholipase D, and phospholipase A2, are discussed. Although f signal transduction much data have been obtained concerning the role of phospholipases C and D in regulating adrenal steroid hormone production, there are still many gaps in our knowledge. Furthermore, little is known about the involvement of phospholipase A2, Endocrinology perhaps, in part, because this enzyme comprises a large family of related enzymes of that are differentially regulated and with different functions. This review presents the evidence supporting the role of each of these phospholipases in steroidogenesis in the Journal Journal of Endocrinology adrenal cortex. (2016) 229, R1–R13 Introduction associated GTP-binding protein exchanges a bound GDP for a GTP. The G protein with GTP bound can then Phospholipids serve a structural function in the cell in that activate the enzyme, phospholipase C (PLC), that cleaves they form the lipid bilayer that maintains cell integrity.
    [Show full text]
  • Essential Role of the Tyrosine Kinase Substrate Phospholipase C-␥1 in Mammalian Growth and Development
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 2999–3003, April 1997 Cell Biology Essential role of the tyrosine kinase substrate phospholipase C-g1 in mammalian growth and development QUN-SHENG JI*, GLENN E. WINNIER†,KEVIN D. NISWENDER‡,DEBRA HORSTMAN*, RON WISDOM*§, MARK A. MAGNUSON‡, AND GRAHAM CARPENTER*§¶ Departments of *Biochemistry, †Cell Biology, ‡Molecular Physiology and Biophysics, and §Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 Communicated by Stanley Cohen, Vanderbilt University School of Medicine, Nashville, TN, January 6, 1997 (received for review November 14, 1996) ABSTRACT The activation of many tyrosine kinases METHODS AND MATERIALS leads to the phosphorylation and activation of phospholipase C-g1 (PLC-g1). To examine the biological function of this PLC-g1 Genomic DNA and Construction of Targeting protein, homologous recombination has been used to selec- Vectors. A 129ySvJ mouse genomic DNA library (Stratagene) tively disrupt the Plcg1 gene in mice. Homozygous disruption was screened using a l-kb mouse cDNA fragment that encodes both SH2 domains of PLC-g1 (11) as a probe (a gift from B. of Plcg1 results in embryonic lethality at approximately 6 embryonic day (E) 9.0. Histological analysis indicates that Margolis, University of Michigan). Of '1 3 10 phage plaques screened, two overlapping clones encompassing 26.6 kb of Plcg1 (2y2) embryos appear normal at E 8.5 but fail to continue normal development and growth beyond E 8.5–E9.0. Plcg1 genomic DNA were obtained. Sequencing of BamHI– These results clearly demonstrate that PLC-g1 with, by in- BamHI subclones identified a 2.9-kb fragment containing ference, its capacity to mobilize second messenger molecules exons corresponding to the X domain and both SH2 domains is an essential signal transducing molecule whose absence is of rat PLC-g1.
    [Show full text]
  • Author's Personal Copy
    Author's personal copy Provided for non-commercial research and educational use only. Not for reproduction, distribution or commercial use. This article was originally published in the book Encyclopedia of Immunobiology, published by Elsevier, and the attached copy is provided by Elsevier for the author's benefit and for the benefit of the author's institution, for non-commercial research and educational use including without limitation use in instruction at your institution, sending it to specific colleagues who you know, and providing a copy to your institution's administrator. All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier’s permissions site at: http://www.elsevier.com/locate/permissionusematerial From Myers, D.R., Roose, J.P., 2016. Kinase and Phosphatase Effector Pathways in T Cells. In: Ratcliffe, M.J.H. (Editor in Chief), Encyclopedia of Immunobiology, Vol. 3, pp. 25–37. Oxford: Academic Press. Copyright © 2016 Elsevier Ltd. unless otherwise stated. All rights reserved. Academic Press Author's personal copy Kinase and Phosphatase Effector Pathways in T Cells Darienne R Myers and Jeroen P Roose, University of California, San Francisco (UCSF), San Francisco, CA, USA Ó 2016 Elsevier Ltd. All rights reserved. Abstract Multiple interconnected effector pathways mediate the activation of T cells following recognition of cognate antigen. These kinase and phosphatase pathways link proximal T cell receptor (TCR) signaling to changes in gene expression and cell physiology.
    [Show full text]
  • 1H HR-MAS and Genomic Analysis of Human Tumor Biopsies Discriminate Between High and Low Grade Astrocytomas Valeria Righi A,B,C, Jose M
    Research Article Received: 16 April 2008, Revised: 22 January 2009, Accepted: 22 January 2009, Published online in Wiley InterScience: 2009 (www.interscience.wiley.com) DOI:10.1002/nbm.1377 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas Valeria Righi a,b,c, Jose M. Rodad, Jose´ Pazd, Adele Muccib, Vitaliano Tugnolic, Gemma Rodriguez-Tarduchya, Laura Barriose, Luisa Schenettib, Sebastia´n Cerda´na* and Marı´a L. Garcı´a-Martı´na,y We investigate the profile of choline metabolites and the expression of the genes of the Kennedy pathway in biopsies of human gliomas (n ¼ 23) using 1H High Resolution Magic Angle Spinning (HR-MAS, 11.7 Tesla, 277 K, 4000 Hz) and individual genetic assays. 1H HR-MAS spectra allowed the resolution and relative quantification by the LCModel of the resonances from choline (Cho), phosphocholine (PC) and glycerophosphorylcholine (GPC), the three main components of the combined tCho peak observed in gliomas by in vivo 1H NMR spectroscopy. All glioma biopsies depicted a prominent tCho peak. However, the relative contributions of Cho, PC, and GPC to tCho were different for low and high grade gliomas. Whereas GPC is the main component in low grade gliomas, the high grade gliomas show a dominant contribution of PC. This circumstance allowed the discrimination of high and low grade gliomas by 1H HR-MAS, a result that could not be obtained using the tCho/Cr ratio commonly used by in vivo 1H NMR spectroscopy. The expression of the genes involved in choline metabolism has been investigated in the same biopsies.
    [Show full text]
  • A New Rnase Sheds Light on the Rnase/Angiogenin Subfamily from Zebrafish
    A new RNase sheds light on the RNase/angiogenin subfamily from zebrafish Pizzo Elio, Antonello Merlino, Mimmo Turano, Irene Russo Krauss, Francesca Coscia, Anna Zanfardino, Mario Varcamonti, Adriana Furia, Concetta Giancola, Lelio Mazzarella, et al. To cite this version: Pizzo Elio, Antonello Merlino, Mimmo Turano, Irene Russo Krauss, Francesca Coscia, et al.. A new RNase sheds light on the RNase/angiogenin subfamily from zebrafish. Biochemical Journal, Portland Press, 2010, 433 (2), pp.345-355. 10.1042/BJ20100892. hal-00549894 HAL Id: hal-00549894 https://hal.archives-ouvertes.fr/hal-00549894 Submitted on 23 Dec 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biochemical Journal Immediate Publication. Published on 04 Nov 2010 as manuscript BJ20100892 TITLE: A new RNase sheds light on the RNase/angiogenin subfamily from zebrafish Authors: Elio PIZZO*, Antonello Merlino†,‡, Mimmo Turano*, Irene Russo Krauss†, Francesca Coscia†, Anna Zanfardino*, Mario Varcamonti*, Adriana Furia*, Concetta Giancola†, Lelio Mazzarella†, ‡, Filomena Sica†, ‡, Giuseppe
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • S41598-021-81940-Y.Pdf
    www.nature.com/scientificreports OPEN Understanding the genetic architecture of the metabolically unhealthy normal weight and metabolically healthy obese phenotypes in a Korean population Jae‑Min Park1,2,5, Da‑Hyun Park3,5, Youhyun Song1, Jung Oh Kim3, Ja‑Eun Choi3, Yu‑Jin Kwon4, Seong‑Jin Kim3, Ji‑Won Lee1* & Kyung‑Won Hong3* Understanding the mechanisms underlying the metabolically unhealthy normal weight (MUHNW) and metabolically healthy obese (MHO) phenotypes is important for developing strategies to prevent cardiometabolic diseases. Here, we conducted genome‑wide association studies (GWASs) to identify the MUHNW and MHO genetic indices. The study dataset comprised genome‑wide single‑nucleotide polymorphism genotypes and epidemiological data from 49,915 subjects categorised into four phenotypes—metabolically healthy normal weight (MHNW), MUHNW, MHO, and metabolically unhealthy obese (MUHO). We conducted two GWASs using logistic regression analyses and adjustments for confounding variables (model 1: MHNW versus MUHNW and model 2: MHO versus MUHO). GCKR, ABCB11, CDKAL1, LPL, CDKN2B, NT5C2, APOA5, CETP, and APOC1 were associated with metabolically unhealthy phenotypes among normal weight individuals (model 1). LPL, APOA5, and CETP were associated with metabolically unhealthy phenotypes among obese individuals (model 2). The genes common to both models are related to lipid metabolism (LPL, APOA5, and CETP), and those associated with model 1 are related to insulin or glucose metabolism (GCKR, CDKAL1, and CDKN2B). This study reveals the genetic architecture of the MUHNW and MHO phenotypes in a Korean population‑based cohort. These fndings could help identify individuals at a high metabolic risk in normal weight and obese populations and provide potential novel targets for the management of metabolically unhealthy phenotypes.
    [Show full text]
  • Cyclic Phosphatidic Acid: an Endogenous Antagonist of Pparγ
    Central Journal of Endocrinology, Diabetes & Obesity Editorial Corresponding author Tamotsu Tsukahara, Department of Hematology and Immunology, Kanazawa Medical University, 1-1 Cyclic Phosphatidic Acid: An Daigaku, Uchinada, Ishikawa 920-0293, Japan, E-mail: ttamotsu@kanazawa-med.ac.jp Submitted: 25 August 2013 Endogenous Antagonist of Accepted: 26 August 2013 Published: 29 August 2013 PPARg Copyright © 2013 Tsukahara et al. Tamotsu Tsukahara1*, Yoshikazu Matsuda2, Hisao Haniu3 and Kimiko Murakami- Murofushi4 OPEN ACCESS 1Department of Hematology and Immunology, Kanazawa Medical University, Japan 2Clinical Pharmacology Educational Center, Nihon Pharmaceutical University, Japan 3Department of Orthopaedic Surgery, Shinshu University School of Medicine, Japan 4Endowed Research Division of Human Welfare Sciences, Ochanomizu University, Japan Lysophospholipids (LPLs) have long been recognized as phosphatidylcholine (PC) to generate choline and bioactive membrane phospholipid metabolites. LPLs are small bioactive lipid, has been implicated in signal transduction, membrane lipid molecules that are characterized by a single carbon 10]. There are two chain and a polar head group. LPLs have been implicated in a PLD isoenzymes, PLD1 and PLD2, which are expressed in a number of pathological states and human diseases. LPLs include varietytrafficking, of tissues and cytoskeletal and cells [ 11reorganization]. We labeled [ cultured cells with lysophosphatidic acid (LPA), alkyl-glycerol phosphate (AGP), [32P]-orthophosphate for 30 min and compared that to [32P]- sphingoshine-1-phosphate, and cyclic phosphatidic acid (cPA). labeled cPA from vehicle control cells using two-dimensional thin In recent years, cPA has been reported to be a target for many layer chromatography. Furthermore, we used CHO cells stably diseases, including obesity [1], atherosclerosis [2], cancer [3], expressing PLD1 or PLD2 or catalytically inactive forms of PLD1 and pain [4].
    [Show full text]
  • Phospholipase D in Cell Proliferation and Cancer
    Vol. 1, 789–800, September 2003 Molecular Cancer Research 789 Subject Review Phospholipase D in Cell Proliferation and Cancer David A. Foster and Lizhong Xu The Department of Biological Sciences, Hunter College of The City University of New York, New York, NY Abstract trafficking, cytoskeletal reorganization, receptor endocytosis, Phospholipase D (PLD) has emerged as a regulator of exocytosis, and cell migration (4, 5). A role for PLD in cell several critical aspects of cell physiology. PLD, which proliferation is indicated from reports showing that PLD catalyzes the hydrolysis of phosphatidylcholine (PC) to activity is elevated in response to platelet-derived growth factor phosphatidic acid (PA) and choline, is activated in (PDGF; 6), fibroblast growth factor (7, 8), epidermal growth response to stimulators of vesicle transport, endocyto- factor (EGF; 9), insulin (10), insulin-like growth factor 1 (11), sis, exocytosis, cell migration, and mitosis. Dysregula- growth hormone (12), and sphingosine 1-phosphate (13). PLD tion of these cell biological processes occurs in the activity is also elevated in cells transformed by a variety development of a variety of human tumors. It has now of transforming oncogenes including v-Src (14), v-Ras (15, 16), been observed that there are abnormalities in PLD v-Fps (17), and v-Raf (18). Thus, there is a growing body of expression and activity in many human cancers. In this evidence linking PLD activity with mitogenic signaling. While review, evidence is summarized implicating PLD as a PLD has been associated with many aspects of cell physiology critical regulator of cell proliferation, survival signaling, such as membrane trafficking and cytoskeletal organization cell transformation, and tumor progression.
    [Show full text]
  • The Design and Synthesis of Autotaxin Inhibitors and Analogs of Lysophosphatidic Acid
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 5-2011 The esiD gn and Synthesis of Autotaxin Inhibitors and Analogs of Lysophosphatidic Acid Renuka Niranjan Gupte University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Chemicals and Drugs Commons, and the Pharmaceutics and Drug Design Commons Recommended Citation Gupte, Renuka Niranjan , "The eD sign and Synthesis of Autotaxin Inhibitors and Analogs of Lysophosphatidic Acid" (2011). Theses and Dissertations (ETD). Paper 112. http://dx.doi.org/10.21007/etd.cghs.2011.0121. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu. The esiD gn and Synthesis of Autotaxin Inhibitors and Analogs of Lysophosphatidic Acid Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Pharmaceutical Sciences Research Advisor Duane D. Miller, Ph.D. Committee Isaac O. Donkor, Ph.D. Richard E. Lee, Ph.D. Wei Li, Ph.D. Gabor J. Tigyi, M.D., Ph.D. DOI 10.21007/etd.cghs.2011.0121 Comments Two year embargo expired May 2013 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/112 THE DESIGN AND SYNTHESIS OF AUTOTAXIN INHIBITORS AND ANALOGS OF LYSOPHOSPHATIDIC ACID A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Renuka Niranjan Gupte May 2011 Copyright © 2011 by Renuka N.
    [Show full text]